## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re	Patent .	Application of				
VEAS	3		Atty. Ref.:	1721-67		
Seria	l No.	cont of 09/913,525	Group:	Unassigned		
Filed:	. A	ugust 19, 2003	Examiner:	Unassigned		
For:		UNOGENIC COMPOSITIONS FOR US CINES	SE AS			
		* * * * * *	* * * *			
		ommissioner for Patents DC 20231	August 19,	2003		
Sir:		INFORMATION DISCLOSUE	RE STATEMEN	<u>r</u>		
$\boxtimes$	1.	PTO-1449 Pursuant to 37 CFR 1.97(b) [within 3 months of filing or prior to 1st Office Action on the merits]  N/C				
	2.(a)	Statement Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)]  N/C				
	2 .(b)	Fee Payment Pursuant to 37 CFR [before Final Office Action or Allowa Statement or Rule 17(p) fee)]	ince (requires R	ule 97(e) <i>\$180.00</i>		
	3.	Pursuant to 37 CFR 1.97(d) [after Final Office Action or Allowand Statement and Rule 17(p) fee), but I	, ,	` ,		
	The fo	ollowing are submitted in the above-ide	entified applicati	on in compliance with		
37 C.	F.R. §§	§ 1.97 and 1.98:				
	4.	A list of documents on Form PTO-144 document has been submitted and mapplication Serial No. 09/913,525. Fu	ade of record in	the parent		

documents are not believed to be required however the office is requested to advise the undersigned if otherwise.

This paper is submitted in accordance with:

$\boxtimes$	5.	37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]				
	6.	37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and				
		a) The required Statement made in item 8 below; or				
		b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.				
	7.	37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and				
		a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and				
		b) The required Statement is stated in item 8 below.				
	8.	Statement under 37 CFR 1.97(e)				
		a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or				
		b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.				
$\boxtimes$	9.	ease charge all deficiency fees associated with the submission of this formation Disclosure Statement and any other fees applicable to this plication to Deposit Account No. 14-1140. An original and one (1) copy of a document are enclosed.				

Respectfully submitted, NIXON & VANDERHYE P.C.

By:

B. J. Sadoff

Reg. No. 36,663

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714

Telephone: (703) 816-4000 Facsimile: (703) 816-4100

Sheet	1	f 2					. •	44			
INFORMATION DISCLOSURE		ATTY.	DOCKET NO.		SERIA	L NO.	<del></del>				
CITATION			1721	1721-67		cont	cont of 09/913,525				
			APPLIC	CANT							
			VEAS	S							
(Use several sheets if necessary)		FILING	FILING DATE		GROU	GROUP					
			Here	Herewith			Unassigned				
			, l	J.S. PATENT DO	CUMENTS		<del></del> -				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME		CLASS	SUBCLASS	FILING IF APPR	DATE OPRIATE	
	++										
	╁┼							<u> </u>			
<del></del>	++									-	
	+ +-										
				-							
	$\bot\bot$										
	-										
				DEION DATE:	5000						
			FC	REIGN PATENT	DOCUMENT	15			TRANS	LATION	
		DOCUMENT	DATE	C	OUNTRY		CLASS	SUBCLASS	YES	NO	
		W/007/26000	07/1007		MIDO			1 ··			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) R. LACASSE ET AL.: "Fusion—competent vaccines: Broad neutralization of primary isolates of HIV." SCIENCE, vol. 283, no. 5400, 15 January 1999 (1999—01—15), pages 357—362, Washington, DC, Etats— J. ROSSIO ET AL.: "Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins." JOURNAL OF VIROLOGY, vol. 72, no. 10, October 1998 (1998—10), pages 7992—8001, Baltimore, MD, Etats—Unis D. MONTEFIORI ET AL.: "Magic of the occult?" SCIENCE, vol. 283, no. 5400, 15 January 1999 (1999—01— 15), pages 336—337, Washington, DC, Etats—Unis D. CHAN ET AL.: "HIV entry and its inhibition." CELL, vol. 93, no. 5, 29 May 1998 (1998—05—29), pages 681—684, Cambridge, MA, Etats—Unis K. SCHONNING ET AL.: "Frosne fusionskomplekser — en genvej til en HIV—vaccine? (Frozen fusion complexes — a shortcut to a HIV—vaccine?)" UGESKRIFT FOR LAEGER, vol. 161, no. 31, 2 August 1999 (1999—08—02), pages 4415—4416, Copenhague, Danemark le titre Q. SATTENTAU ET AL.: "Antibody neutralization of HIV—1 and the potential for-vaccine design." MMUNOLOGY LETTERS, vol. 66, no. 1—3, March 1999 (1999—03), pages 143—149, Amsterdam, Pays-

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include

**Date Considered** 

\*Examiner

copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

## INFORMATION DISCLOSURE CITATION

	~, *
Atty. Docket No.	Serial No.
1721-67	<b>cont</b> of 09/913,525
Applicant	
VEAS	
Filing Date	Group
Herewith	Unassign d

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) Riffkin et al. "A single amino-acid change between the antigenically different extracellular serine proteases V2 and B2 from Dichelobacter nodosus", Gene, Vol. 167 (1995), pp. 279-283. Abaza et al. "Effects of amino acid substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide immunization", Journal of Protein Chemistry, Vol. 11, No. 5 (1992), pp 433-444. Cruse et al. Illustrated Dictionary of Immunology (Boca Raton, FL, CRC Press, Inc., 1995), p. 309, QR180.4.C78. Paul, Fundamental Immunology, (Philadelphia & New York, Lippincott-Raven Publishers, 1993), pp. 250 and 1311-1312. QR181.F84. Cohen et al. "Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, Vol. 96, Issue 19(Sep. 14, 1999), pp. 10842-10847. Schønning et al. "Frosne fusionskomplekser-en genvej til en HIV-vaccine?", Ugeskrift for Laeger, Vol. 161, No. 31 (1999 Aug 2), pp. 4415-6. Devico et al. "Monoclonal Antibodies Raised against Covalently Crosslinked Complexes of Human Immunodeficiency Virus Type 1 gp 120 and CD4 Receptor Identify a Novel Complex-Dependent Epitope on gp 120", Virology, Vol. 211, No. 2(20 Aug 1995), pp 583-588. Kwong et al. "Structure of an HIV gp 120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody", Nature, Vol. 393, No. 6686 (1998), pp. 648-659. Rigaud et al. "Reconstitution of membrane proteins into liposomes: application to energy-transducing membrane proteins", review in Biochimica et Biophysica Acta, Vol. 1231 (1995) pp. 223-246. Riley et al. "Native and Memory CD4 T Cells Differ in Their Susceptibilities to Human Immunodeficiency Virus Type 1 Infection following CD28 Costimulation: Implications for Transmission and Pathogenesis", Journal of Virology, Vol. 72, No. 10(Oct. 1998) pp. 8-273-8280. **Date Considered** \*Examiner

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)